Search

Your search keyword '"Burdach, S."' showing total 974 results
Start Over Author "Burdach, S."
974 results on '"Burdach, S."'

1. No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., Schober, S. J., Ranft, A., Gassmann, H., Jabar, S., Gall, K., von Lüttichau, I., Wawer, A., Koscielniak, E., Diaz, M. A., Ussowicz, M., Kazantsev, I., Afanasyev, B., Merker, M., Klingebiel, T., Prete, A., Gruhn, B., Bader, P., Jürgens, H., Dirksen, U., Handgretinger, R., Burdach, S., and Lang, P.

Published
2021
Full Text
View/download PDF

6. Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., Schober, S. J., Ranft, A., Gassmann, H., Jabar, S., Gall, K., von Lüttichau, I., Wawer, A., Koscielniak, E., Diaz, M. A., Ussowicz, M., Kazantsev, I., Afanasyev, B., Merker, M., Klingebiel, T., Prete, A., Gruhn, B., Bader, P., Jürgens, H., Dirksen, U., Handgretinger, R., Burdach, S., and Lang, P.

Published
2021
Full Text
View/download PDF

10. Leukämien

Author

Jürgens, H., Burdach, S., Göbel, U., and Reinhardt, Dietrich, editor

Published
2007
Full Text
View/download PDF

14. Leukämien

Author

Jürgens, H., Burdach, S., Göbel, U., and Reinhardt, Dietrich, editor

Published
2004
Full Text
View/download PDF

19. Pharmacological Gene Therapy for Experimental Brain Tumors

Author

Fischer, U., Rainov, N. G., Frank, S., Steffens, S., Heidmann, O., Gorelow, V., Burdach, S. E. G., Kramm, C. M., Berdel, W. E., editor, Büchner, Th., editor, Kienast, J., editor, Van De Loo, J., editor, Jürgens, H., editor, Ritter, J., editor, and Vormoor, J., editor

Published
2000
Full Text
View/download PDF

24. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients

Author

Thiel, U., Wawer, A., Wolf, P., Badoglio, M., Santucci, A., Klingebiel, T., Basu, O., Borkhardt, A., Laws, H.-J., Kodera, Y., Yoshimi, A., Peters, C., Ladenstein, R., Pession, A., Prete, A., Urban, E.-C., Schwinger, W., Bordigoni, P., Salmon, A., Diaz, M.A., Afanasyev, B., Lisukov, I., Morozova, E., Toren, A., Bielorai, B., Korsakas, J., Fagioli, F., Caselli, D., Ehninger, G., Gruhn, B., Dirksen, U., Abdel-Rahman, F., Aglietta, M., Mastrodicasa, E., Torrent, M., Corradini, P., Demeocq, F., Dini, G., Dreger, P., Eyrich, M., Gozdzik, J., Guilhot, F., Holler, E., Koscielniak, E., Messina, C., Nachbaur, D., Sabbatini, R., Oldani, E., Ottinger, H., Ozsahin, H., Schots, R., Siena, S., Stein, J., Sufliarska, S., Unal, A., Ussowicz, M., Schneider, P., Woessmann, W., Jürgens, H., Bregni, M., and Burdach, S.

Published
2011
Full Text
View/download PDF

26. Besondere Therapiemaßnahmen

Author

Lemburg, P., Schaub, J., Schröder, H., Janssen, F., Poschmann, A., Bender-Götze, C., Burdach, S., Reinhardt, D., and Reinhardt, Dietrich, editor

Published
1994
Full Text
View/download PDF

29. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008

Author

Whelan, J., Deley, M.C. le, Dirksen, U., Teuff, G. le, Brennan, B., Gaspar, N., Hawkins, D.S., Amler, S., Bauer, S., Bielack, S., Blay, J.Y., Burdach, S., Castex, M.P., Dilloo, D., Eggert, A., Gelderblom, H., Gentet, J.C., Hartmann, W., Hassenpflug, W.A., Hjorth, L., Jimenez, M., Klingebiel, T., Kontny, U., Kruseova, J., Ladenstein, R., Laurence, V., Lervat, C., Marec-Berard, P., Marreaud, S., Michon, J., Morland, B., Paulussen, M., Ranft, A., Reichardt, P., Berg, H. van den, Wheatley, K., Judson, I., Lewis, I., Craft, A., Juergens, H., Oberlin, O., Euro- E W I N G 99 Investigator, EWING-2008 Investigator, Paediatric Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
0301 basic medicine, Melphalan, Cancer Research, medicine.medical_specialty, Vincristine, medicine.medical_treatment, Medizin, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Original Reports, Medicine, Etoposide, Chemotherapy, Ifosfamide, business.industry, Hazard ratio, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Sarcoma, business, Busulfan, medicine.drug
Abstract

Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis ≥ 200 mL if unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year event-free survival (EFS) was sought (hazard ratio [HR], 0.60). Results Between 2000 and 2015, 240 patients classified as high risk (median age, 17.1 years) were randomly assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat analysis, the risk of event was significantly decreased by BuMel compared with VAI: HR, 0.64 (95% CI, 0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0% (95% CI, 60.2% to 76.6%) versus 56.7% (95% CI, 47.6% to 65.4%) and 60.7% (95% CI, 51.1% to 69.6%) versus 47.1% (95% CI, 37.7% to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and 8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to 79.6%) and 64.5% (95% CI, 54.4% to 73.5%) versus 55.6% (95% CI, 45.8% to 65.1%). Results were consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after standard chemotherapy. Significantly more BuMel patients experienced severe acute toxicities from this course of chemotherapy compared with multiple VAI courses. Conclusion BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction in localized ES with predefined high-risk factors. For this group of patients, BuMel may be an important addition to the standard of care.

Published
2018

30. Recombinant Human Erythropoietin After Bone Marrow Transplantation — A Placebo Controlled Trial

Author

Link, H., Boogaerts, M. A., Fauser, A., Or, R., Reiffers, J., Gorin, N. C., Carella, A., Mandelli, F., Burdach, S., Ferrant, A., Linkesch, W., Tura, S., Bacigalupo, A., Schindel, F., Heinrichs, H., Hiddemann, W., editor, Plunkett, W., editor, Büchner, T., editor, Ritter, J., editor, Wörmann, B., editor, Keating, M. J., editor, and Creutzig, U., editor

Published
1996
Full Text
View/download PDF

35. ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED RHABDOMYOSARCOMA: A RETROSPECTIVE ASSESSMENT: PH-AB118

Author

Thiel, U., Koscielniak, E., Blaeschke, F., Grunewald, T. G. P., Badoglio, M., Diaz, Angel M., Paillard, C., Prete, A., Ussowicz, M., Lang, P., Fagioli, F., Lutz, P., Ehninger, G., Schneider, P., Santucci, A., Bader, P., Gruhn, B., Faraci, M., Antunovic, P., Styczynski, J., Krüger, W. H., Castagna, L., Rohrlich, P., Ouachee, M., Salmon, A., Peters, C., Bregni, M., and Burdach, S.

Published
2014

36. CLINICAL IMPACT OF POST-TRANSPLANT CHIMERISM MONITORING IN CD33/34 BONE MARROW SUBPOPULATIONS AND WHOLE PERIPHERAL BLOOD IN PEDIATRIC AML: PROSPECTIVE COMPARISON OF HIGHLY SENSITIVE REAL TIME SEQUENCE POLYMORPHISM PCR VERSUS GOLD-STANDARD STR-PCR: PH-O097

Author

Willasch, Manfred A., Rettinger, E., Zabel, M., Kreyenberg, H., Meyer, V., Merker, M., Borkhardt, A., Metzler, M., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M., Schlegel, P.-G., Klingebiel, T., and Bader, P.

Published
2014

39. Sarcoma treatment in the era of molecular medicine

Author

Grünewald, T.G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre-Aranaz, F., Pompo, G. Di, Distel, M., Dorado-Garcia, H., Garcia-Castro, J., González-González, L., Grigoriadis, A.E., Kasan, M., Koelsche, C., Krumbholz, M., Lecanda, F., Lemma, S., Longo, D.L., Madrigal-Esquivel, C., Morales-Molina, Á., Musa, J., Ohmura, S., Ory, B., Pereira-Silva, M., Perut, F., Rodriguez, R., Seeling, C., Shaaili, N. Al, Shaabani, S., Shiavone, K., Sinha, S., Tomazou, E.M., Trautmann, M., Vela, M., Versleijen-Jonkers, Y.M.H., Visgauss, J., Zalacain, M., Schober, S.J., Lissat, A., English, W.R., Baldini, N., Heymann, D., Grünewald, T.G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre-Aranaz, F., Pompo, G. Di, Distel, M., Dorado-Garcia, H., Garcia-Castro, J., González-González, L., Grigoriadis, A.E., Kasan, M., Koelsche, C., Krumbholz, M., Lecanda, F., Lemma, S., Longo, D.L., Madrigal-Esquivel, C., Morales-Molina, Á., Musa, J., Ohmura, S., Ory, B., Pereira-Silva, M., Perut, F., Rodriguez, R., Seeling, C., Shaaili, N. Al, Shaabani, S., Shiavone, K., Sinha, S., Tomazou, E.M., Trautmann, M., Vela, M., Versleijen-Jonkers, Y.M.H., Visgauss, J., Zalacain, M., Schober, S.J., Lissat, A., English, W.R., Baldini, N., and Heymann, D.

Abstract

Contains fulltext : 229496.pdf (publisher's version ) (Open Access), Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results